JP6640083B2 - 肺高血圧症を治療するための組成物および方法 - Google Patents

肺高血圧症を治療するための組成物および方法 Download PDF

Info

Publication number
JP6640083B2
JP6640083B2 JP2016533067A JP2016533067A JP6640083B2 JP 6640083 B2 JP6640083 B2 JP 6640083B2 JP 2016533067 A JP2016533067 A JP 2016533067A JP 2016533067 A JP2016533067 A JP 2016533067A JP 6640083 B2 JP6640083 B2 JP 6640083B2
Authority
JP
Japan
Prior art keywords
tgf
ligand
pharmaceutical composition
tgfbrii
capturer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016533067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501977A (ja
JP2017501977A5 (enExample
Inventor
ポール ユ
ポール ユ
アシャ グリンバーグ
アシャ グリンバーグ
ダイアン エス． サコ
ダイアン エス． サコ
ローズライン キャストングアイ
ローズライン キャストングアイ
リタ スティーブス
リタ スティーブス
ラヴィンドラ クマー
ラヴィンドラ クマー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of JP2017501977A publication Critical patent/JP2017501977A/ja
Publication of JP2017501977A5 publication Critical patent/JP2017501977A5/ja
Priority to JP2019233811A priority Critical patent/JP6952100B2/ja
Application granted granted Critical
Publication of JP6640083B2 publication Critical patent/JP6640083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2016533067A 2013-11-21 2014-11-21 肺高血圧症を治療するための組成物および方法 Active JP6640083B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019233811A JP6952100B2 (ja) 2013-11-21 2019-12-25 肺高血圧症を治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907260P 2013-11-21 2013-11-21
US61/907,260 2013-11-21
PCT/US2014/066776 WO2015077540A2 (en) 2013-11-21 2014-11-21 Compositions and methods for treating pulmonary hypertension

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019233811A Division JP6952100B2 (ja) 2013-11-21 2019-12-25 肺高血圧症を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2017501977A JP2017501977A (ja) 2017-01-19
JP2017501977A5 JP2017501977A5 (enExample) 2018-04-05
JP6640083B2 true JP6640083B2 (ja) 2020-02-05

Family

ID=53180397

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016533067A Active JP6640083B2 (ja) 2013-11-21 2014-11-21 肺高血圧症を治療するための組成物および方法
JP2019233811A Active JP6952100B2 (ja) 2013-11-21 2019-12-25 肺高血圧症を治療するための組成物および方法
JP2021156343A Active JP7474729B2 (ja) 2013-11-21 2021-09-27 肺高血圧症を治療するための組成物および方法
JP2024065676A Pending JP2024096891A (ja) 2013-11-21 2024-04-15 肺高血圧症を治療するための組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019233811A Active JP6952100B2 (ja) 2013-11-21 2019-12-25 肺高血圧症を治療するための組成物および方法
JP2021156343A Active JP7474729B2 (ja) 2013-11-21 2021-09-27 肺高血圧症を治療するための組成物および方法
JP2024065676A Pending JP2024096891A (ja) 2013-11-21 2024-04-15 肺高血圧症を治療するための組成物および方法

Country Status (9)

Country Link
US (3) US10682392B2 (enExample)
EP (4) EP4005585B1 (enExample)
JP (4) JP6640083B2 (enExample)
CN (2) CN105934249A (enExample)
AU (3) AU2014352843B2 (enExample)
CA (1) CA2931309C (enExample)
DK (2) DK3071215T3 (enExample)
ES (2) ES2902533T3 (enExample)
WO (1) WO2015077540A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
ES2902533T3 (es) * 2013-11-21 2022-03-28 Brigham & Womens Hospital Inc Composiciones y métodos para tratar la hipertensión pulmonar
EP3174550B1 (en) * 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
US20200231652A1 (en) * 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
DK3496739T3 (da) 2016-07-15 2021-05-10 Acceleron Pharma Inc Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
BR112019005964A2 (pt) * 2016-09-27 2019-06-18 Epicentrx, Inc. proteínas de fusão imunomoduladoras
AU2018228435C1 (en) * 2017-03-02 2025-09-18 National Research Council Of Canada TGF-beta-receptor ectodomain fusion molecules and uses thereof
ES2948647T3 (es) 2017-05-04 2023-09-15 Acceleron Pharma Inc Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas
MY202480A (en) 2017-05-12 2024-04-30 Shanghai hengrui pharmaceutical co ltd Fusion protein containing tgf- receptor and medicinal uses thereof
JP2020536518A (ja) 2017-09-27 2020-12-17 エピセントアールエックス，インコーポレイテッド 免疫調節融合タンパク質
WO2019173692A2 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
US11168138B2 (en) 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
US12559539B2 (en) 2018-11-09 2026-02-24 Jiangsu Hengrui Medicine Co., Ltd. TGF-beta receptor fusion protein pharmaceutical composition and use thereof
CN112239507A (zh) 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
US20220362333A1 (en) * 2019-07-26 2022-11-17 Board Of Trustees Of Michigan State University Methods Of Preventing Or Treating Fatty Degeneration Of Skeletal Muscle
US20210061871A1 (en) * 2019-08-29 2021-03-04 Nantbio, Inc. Modified N-810 and Methods Therefor
TW202128763A (zh) * 2019-11-12 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 含有ＴＧＦ－β受體的融合蛋白及其醫藥用途
US20230174620A1 (en) 2020-04-28 2023-06-08 Acceleron Pharma Inc. Actrii proteins and use in treating post-capillary pulmonary hypertension
US20250152670A1 (en) * 2022-04-28 2025-05-15 Wenzhou Prarucom Bio-Chemical Technology Co. Method for alleviating pulmonary fibrosis using epidermal growth factor

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
NZ500284A (en) 1997-04-18 2001-09-28 Biogen Inc Type II TGF-beta receptor fusion proteins
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
AU4572899A (en) 1998-06-16 2000-01-05 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CA2390820A1 (en) 2002-06-17 2003-12-17 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
KR20050054977A (ko) * 2002-10-14 2005-06-10 소시에떼 드 테크놀로지 미쉐린 대칭 힘으로 분산된 비드를 포함하는 연장 이동성 타이어
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
GB0514259D0 (en) 2005-07-12 2005-08-17 Renovo Ltd Pharmaceutical compositions
US20080009500A1 (en) * 2005-11-08 2008-01-10 Michael Kahn Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders
US8454952B2 (en) 2006-03-13 2013-06-04 The Johns Hopkins University Augmentation of endothelial thromboresistance
EP2029625A2 (en) 2006-06-05 2009-03-04 Novartis AG Use of tgf-beta antagonists in treatment of parathyroid-related disorders
CN100588717C (zh) 2007-03-21 2010-02-10 中国医学科学院阜外心血管病医院 生长分化因子15基因多态位点在预测高血压继发左心室肥厚中的用途
MX2010002005A (es) 2007-08-22 2010-03-11 Irm Llc Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.
EP2037275A1 (en) 2007-09-11 2009-03-18 F. Hoffmann-La Roche AG Differentiation of different causes of right heart failure
KR101008385B1 (ko) 2008-08-01 2011-01-14 한국과학기술연구원 다환 방향족 탄화수소류 노출 여부 확인용 바이오마커 및이를 이용한 확인 방법
EP2326670A4 (en) 2008-09-17 2014-04-16 Nat Res Council Canada HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY
WO2011088148A1 (en) 2010-01-12 2011-07-21 Isis Pharmaceuticals, Inc. Modulation of transforming growth factor-beta 1 expression
EP2372364A1 (en) 2010-03-31 2011-10-05 Medizinische Hochschule Hannover Biomarker for pulmonary hypertension
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US20130287688A1 (en) 2010-11-18 2013-10-31 Xtuit Pharmaceuticals, Inc. Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2012093125A1 (en) * 2011-01-06 2012-07-12 Glaxo Group Limited Ligands that bind tgf-beta receptor ii
JP6250533B2 (ja) 2011-04-20 2017-12-20 アクセレロン ファーマ インコーポレイテッドＡｃｃｅｌｅｒｏｎ Ｐｈａｒｍａ，Ｉｎｃ． エンドグリンポリペプチドおよびその使用
CN103732623B (zh) 2011-06-03 2017-09-29 佐马技术有限公司 对TGF‑β具有特异性的抗体
EP2739645B1 (en) 2011-08-01 2018-12-19 Tufts Medical Center, Inc. Endoglin-specific antibody for use in a method of treating heart failure and related conditions
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
AU2013202269A1 (en) 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
WO2013188787A1 (en) 2012-06-15 2013-12-19 The General Hospital Corporation INHIBITORS OF MICRORNAs THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF
EP2597466A1 (en) 2012-06-26 2013-05-29 Roche Diagniostics GmbH Means and methods for proSP-B based diagnosis of alveolar damage in pulmonary hypertension patients
RS59045B1 (sr) 2012-09-26 2019-08-30 Univ Wuerzburg J Maximilians Monoklonalna antitela za faktor 15 rasta i diferencijacije (gdf-15)
ES2791183T3 (es) 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
EP3747457A3 (en) 2013-01-17 2021-03-03 Medizinische Hochschule Hannover Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
KR101346132B1 (ko) 2013-02-18 2013-12-31 강원대학교산학협력단 Mic-1의 혈관신생유도 기능을 억제하는 항 mic-1 단일클론항체 mbm-14
KR101346181B1 (ko) 2013-02-18 2014-01-03 강원대학교산학협력단 Mic-1의 혈관신생유도 기능을 억제하는 항 mic-1 단일클론항체 mbm-12
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
ES2902533T3 (es) * 2013-11-21 2022-03-28 Brigham & Womens Hospital Inc Composiciones y métodos para tratar la hipertensión pulmonar
DK3145493T3 (da) 2014-05-18 2022-10-31 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende exosomer
US20170100460A1 (en) 2014-06-13 2017-04-13 Novartis Ag Use of serelaxin to reduce gdf-15
JP6910800B2 (ja) 2014-06-20 2021-07-28 アベオ ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
EP3174550B1 (en) * 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法

Also Published As

Publication number Publication date
CA2931309A1 (en) 2015-05-28
EP4005585A1 (en) 2022-06-01
AU2014352843B2 (en) 2020-03-05
ES2778201T3 (es) 2020-08-10
JP2020073528A (ja) 2020-05-14
JP2024096891A (ja) 2024-07-17
EP4417255A3 (en) 2024-10-23
AU2023263573A1 (en) 2023-11-30
EP3685848B1 (en) 2021-09-15
CA2931309C (en) 2022-06-21
AU2020203110A1 (en) 2020-06-11
WO2015077540A2 (en) 2015-05-28
EP3071215A4 (en) 2017-08-23
EP3071215A2 (en) 2016-09-28
US20200323955A1 (en) 2020-10-15
ES2902533T3 (es) 2022-03-28
JP7474729B2 (ja) 2024-04-25
JP6952100B2 (ja) 2021-10-20
EP4417255A2 (en) 2024-08-21
US10682392B2 (en) 2020-06-16
EP3071215B1 (en) 2020-01-08
JP2017501977A (ja) 2017-01-19
US11951156B2 (en) 2024-04-09
JP2021193139A (ja) 2021-12-23
US20160287664A1 (en) 2016-10-06
EP3685848A1 (en) 2020-07-29
AU2014352843A1 (en) 2016-06-16
CN105934249A (zh) 2016-09-07
CN120919282A (zh) 2025-11-11
US20240366720A1 (en) 2024-11-07
DK3071215T3 (da) 2020-03-23
EP4005585B1 (en) 2024-03-27
DK3685848T3 (da) 2021-12-13
WO2015077540A3 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
JP7474729B2 (ja) 肺高血圧症を治療するための組成物および方法
CN107108711B (zh) 包含肽变异体的药物组合物及其使用方法
ES2472791T3 (es) Polip�ptidos natriur�ticos
JP7854402B2 (ja) 肺動脈性肺高血圧症（ｐａｈ）の処置のためのａｃｔｒｉｉタンパク質
CN111100197A (zh) 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂
AU2016332062A1 (en) Treatment of bile acid disorders
US20130058941A1 (en) Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases
CN117794562A (zh) ActRII蛋白及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191225

R150 Certificate of patent or registration of utility model

Ref document number: 6640083

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250